Saturday 17 October 2026
Export BCAX’s income statement to Excel — free account
Bicara Therapeutics Inc.
BCAX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 64.0% and free cash flow fell 73.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
16.78
0.84
−4.77%
Follow BCAX
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 16.01 | 7.80 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 28.09 | 19.71 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 32 | 55 | 103 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | — | — | — | — | (52) | (68) | (138) | |||||
| EBT margin, % | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | — | — | — | — | — | — | (52) | (68) | (138) | |||||
| Depreciation | — | — | — | — | — | — | — | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | — | — | (89.61) | (4.05) | (2.52) | |||||
| Cash flow | — | — | — | — | — | — | — | (78.66) | (4.45) | (1.95) | |||||
| Capex | — | — | — | — | — | — | — | (1.01) | 0.00 | (0.01) | |||||
| Free cash flow | — | — | — | — | — | — | — | (79.67) | (4.45) | (1.96) | |||||
| Book value | — | — | — | — | — | — | — | (256.45) | 29.27 | 7.34 | |||||
| Shares, m | — | — | — | — | — | — | — | 1 | 17 | 55 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (46) | (75) | (107) | ||||
| Capex | — | — | — | — | — | — | — | (1) | 0 | 0 | |||||
| Free cash flow | — | — | — | — | — | — | — | (46) | (75) | (107) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | 216 | 485 | 393 | ||||
| Total debt | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | — | — | — | — | — | — | — | (230) | (490) | (415) | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | (149) | 492 | 401 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (18.28) | (29.32) | ||||
| ROIC | — | — | — | — | — | — | — | 0.00 | (2,379.53) | 0.00 | |||||
| ROE | — | — | — | — | — | — | — | 0.00 | (39.63) | (30.88) | |||||
Negative figures in brackets.
Charts ten years each
Bicara Therapeutics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| DRTS Alpha Tau Medical Ltd. | $1.2B | — (loss-making) | — | — | n/m | −30.42% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| SNDX Syndax Pharmaceuticals, Inc. | $1.2B | — (loss-making) | — (loss-making) | +91.76% (above 0%: growing) | n/m | +65.47% (above 0%: growing) | 95.59% | (54.95%) | Compare |
| TSHA Taysha Gene Therapies, Inc. | $1.2B | — (loss-making) | — (loss-making) | +206.77% (above 0%: growing) | n/m | −100.28% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| LBRX LB Pharmaceuticals Inc | $1.2B | — (loss-making) | — | — | n/m | −579.03% (below 0%: shrinking) | — | 0.00% | Compare |
| BCAX Bicara Therapeutics Inc. | $1.2B | — (loss-making) | — | — | n/m | −72.95% (below 0%: shrinking) | — | 0.00% | |
| DMRA Galecto, Inc. | $1.2B | — (loss-making) | — | — | n/m | −877.51% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| VOR Vor Biopharma Inc. | $1.1B | — (loss-making) | — | — | n/m | −47.59% (below 0%: shrinking) | 0.00% | — | Compare |
| NBTX Nanobiotix S.A. - Sponsored ADR | $1.1B | — (loss-making) | — | −71.69% (below 0%: shrinking) | n/m | −177.26% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| REPL Replimune Group, Inc. | $1.1B | — (loss-making) | — | — | n/m | +5.04% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $1.2B | — | — | +91.76% | — | −73.93% | 0.00% | 0.00% |
Bicara Therapeutics Inc. (BCAX) key facts
- Bicara Therapeutics Inc. (BCAX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, BCAX traded at $16.78, a market capitalization of $1.2 billion.
- Return on equity was −30.9% and debt-to-equity 0.00.